Atomoxetine Drug Classification
Atomoxetine (Strattera) is classified as a selective norepinephrine reuptake inhibitor (SNRI), specifically a nonstimulant medication approved for the treatment of ADHD. 1, 2
Mechanism of Action
Atomoxetine increases synaptic noradrenaline by selectively binding to the norepinephrine transporter, thereby inhibiting norepinephrine reuptake. 1
In the prefrontal cortex specifically, atomoxetine also increases dopamine levels because norepinephrine transporters are responsible for dopamine reuptake in this brain region where dopamine transporters are scarce. 1
The FDA label confirms atomoxetine is structurally a phenoxypropylamine derivative and is related to the antidepressant fluoxetine, though it functions as a selective norepinephrine reuptake inhibitor rather than an SSRI. 2, 3
Clinical Classification Context
Atomoxetine is categorized as a nonstimulant ADHD medication, distinguishing it from first-line stimulant treatments like methylphenidate and amphetamines. 1, 4, 5
Current ADHD treatment guidelines generally recommend nonstimulants like atomoxetine as second-line treatment, with stimulants remaining first-line due to larger effect sizes. 1
Atomoxetine is not a controlled substance in the United States, unlike stimulant medications, because it carries negligible risk of abuse or diversion. 6, 7, 8
Important Clinical Distinction
While atomoxetine was initially developed as an antidepressant, evidence does not support its efficacy for treating depression. 1
The drug's classification as a norepinephrine reuptake inhibitor should not be confused with its clinical indication—it is FDA-approved specifically for ADHD treatment in children, adolescents, and adults, not for depression or anxiety disorders. 1